Business context and reporting period
This is Novus Therapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2019, filed August 13, 2019. The filing is for Novus Therapeutics, not Eledon Pharmaceuticals as stated in the request metadata. Novus was a development-stage ENT pharmaceutical company, focused primarily on OP0201, a nasal aerosol candidate for otitis media. It had no approved products or product-sales revenue.
Financial results and liquidity
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Revenue | $0 reported | $0 reported | $0 reported | $0 reported |
| Research and development | $2.297 million | $1.329 million | $5.286 million | $2.426 million |
| General and administrative | $1.792 million | $1.860 million | $3.678 million | $3.558 million |
| Total operating expenses | $4.089 million | $3.189 million | $8.964 million | $5.984 million |
| Net loss | $4.093 million | $3.189 million | $8.974 million | $5.995 million |
| Basic and diluted loss per share | $0.35 | $0.34 | $0.85 | $0.70 |
At June 30, 2019, cash was $13.703 million, working capital was $13.2 million, total assets were $18.216 million, and total liabilities were $2.184 million. No interest-bearing debt was reported; liabilities included $409,000 in operating lease obligations. Six-month operating cash use was $8.945 million, offset by $9.676 million of financing cash inflows, leaving cash up $731,000 from year-end 2018. No investing cash flows were reported. The filing states that cash was insufficient to fund operations for 12 months after issuance of the financial statements and that substantial doubt existed about the company’s ability to continue as a going concern.
Material changes versus the prior comparable period
- Six-month R&D expense rose 118% to $5.286 million, primarily from $2.5 million of higher OP0201 clinical costs. Quarterly R&D increased 73%, also mainly due to OP0201 clinical costs.
- Six-month operating expenses increased 50% and net loss increased 50%. The loss per share widened to $0.85 from $0.70.
- Operating cash use increased to $8.945 million from $5.605 million for the first half of 2018; financing inflows rose to $9.676 million from $7.491 million.
- The April 2019 registered direct offering raised approximately $10.7 million gross through the sale of 3,449,112 shares. Associated warrants could permit purchases of up to 6,898,224 additional shares at $4.00, subject to their terms, plus placement-agent warrants. Common shares outstanding increased to 12,974,923 from 9,422,143 at year-end 2018.
Outlook, commentary, risks and unusual items
- Management expected R&D expenses to increase as OP0201 advances; recurring quarterly G&A was expected to remain flat for the remainder of 2019. No revenue or earnings guidance was provided.
- The company said existing cash could fund completion of the ongoing OP0201 Phase 2a study, but additional capital would be needed for further studies and potential commercialization. It was pursuing cost reductions and described strategic alternatives; the filing provides no specific outcome.
- Financing may require further equity or debt, collaborations, licensing, or reductions or delays to development. Management warned that lack of financing could force curtailment of research or clinical programs. The financial statements were prepared on a going-concern basis without adjustments for the uncertainty.
- On August 8, 2019, Nasdaq notified Novus that it failed the $1.00 minimum bid-price requirement. It had until February 4, 2020 to regain compliance; delisting could impair access to capital and trading liquidity.
- The OP0201 Phase 2a study in infants and children was exploratory. Key risks included clinical and regulatory failure, manufacturing scale-up and reliance on sole-source suppliers, and the need for additional financing. The company reported no material contingency accruals. Securities litigation related to Tokai’s 2014 IPO remained pending: one action was dismissed with prejudice, while the Jackie888 and Angelos actions remained unresolved; potential losses could not be estimated.
- The company adopted lease accounting in 2019 and recorded a $489,000 right-of-use asset and $491,000 lease liability at adoption. No goodwill impairment was identified at June 30, 2019.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Novus Therapeutics, Inc., not Eledon Pharmaceuticals.
- Assess cash runway against the reported $8.945 million first-half operating cash use and the explicit going-concern warning.
- Track financing needs, dilution potential from outstanding warrants, and progress on strategic alternatives and cost reductions.
- Verify OP0201 Phase 2a timing, results, and the funding required for subsequent clinical development.
- Monitor Nasdaq bid-price compliance and developments in the pending IPO-related litigation.